POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
- TRADE NAME: Biktarvy (Gilead)
- INDICATIONS: HIV-1 infection
- CLASS: Antiretroviral, Hepatitis B virus necleoside analog reverse transcriptase inhibitor (tenofovir alafenamide), Integrase strand transfer inhibitor (bictegravir), Nucleoside analog reverse transcriptase inhibitor (emtricitabine)
- HALF-LIFE: 17 hours (bictegravir); 10 hours (emtricitabine); <1 hour (tenofovir alafenamide)
- FDA APPROVAL DATE: 02/07/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Dofetilide, Metformin, Other antiretroviral drugs, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort - PREGNANCY: Insufficient evidence to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/07/2024
